keyword
MENU ▼
Read by QxMD icon Read
search

personalized oncology

keyword
https://www.readbyqxmd.com/read/29166754/advances-in-oncological-treatment-limitations-of-recist-1-1-criteria
#1
Serena Grimaldi, Marie Terroir, Caroline Caramella
INTRODUCTION: RECIST 1.1 criteria are the standard for the response assessment of most solid tumors on computed tomography (CT). Nevertheless, the emergence of new classes of treatment in the lasts decades has brought new challenges in the response evaluation. EVIDENCE ACQUISITION: A PubMed online database literature search was performed in order to identify papers in English with full text available published up to September 2017. EVIDENCE SYNTHESIS: Some oncologic treatments, such as anti-angiogenic agents, immunotherapy and local treatments, have proven to be effective despite atypical patterns of responses...
November 22, 2017: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29158373/revisiting-expectations-in-an-era-of-precision-oncology
#2
Emily J Marchiano, Andrew C Birkeland, Paul L Swiecicki, Kayte Spector-Bagdady, Andrew G Shuman
As we enter an era of precision medicine and targeted therapies in the treatment of metastatic cancer, we face new challenges for patients and providers alike as we establish clear guidelines, regulations, and strategies for implementation. At the crux of this challenge is the fact that patients with advanced cancer may have disproportionate expectations of personal benefit when participating in clinical trials designed to generate generalizable knowledge. Patient and physician goals of treatment may not align, and reconciliation of their disparate perceptions must be addressed...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29156447/pd-1-blockade-in-advanced-nsclc-a-focus-on-pembrolizumab
#3
REVIEW
Solange Peters, Keith M Kerr, Rolf Stahel
Non-small cell lung cancer (NSCLC) is one of the most prevalent cancers and is responsible for a large proportion of all cancer-related deaths. Current treatment options are inadequate, reflecting a substantial unmet clinical need. Increasing knowledge regarding the mechanisms and genetic aberrations underlying tumor development and growth has heralded a new era of therapy in oncology, moving away from indiscriminate cytotoxic chemotherapy toward more finely focused, targeted medicine. The development of small-molecule drugs and monoclonal antibodies directed toward specific components of dysfunctional molecular or immune pathways, and mutated genes specific to particular cancer types, is leading the field to more personalized and less toxic treatment options, many of which have demonstrated greater efficacy and survival benefits than their chemotherapeutic counterparts...
October 23, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29153081/risks-and-benefits-of-twitter-use-by-hematologists-oncologists-in-the-era-of-digital-medicine
#4
REVIEW
Deanna J Attai, Patricia F Anderson, Michael J Fisch, David L Graham, Matthew S Katz, Jennifer Kesselheim, Merry Jennifer Markham, Nathan A Pennell, Mina S Sedrak, Michael A Thompson, Audun Utengen, Don S Dizon
Twitter use by physicians, including those in the hematology-oncology field, is increasing. This microblogging platform provides a means to communicate and collaborate on a global scale. For the oncology professional, an active Twitter presence provides opportunities for continuing medical education, patient engagement and education, personal branding, and reputation management. However, because Twitter is an open, public forum, potential risks such as patient privacy violations, personal information disclosures, professionalism lapses, and time management need to be considered and managed...
October 2017: Seminars in Hematology
https://www.readbyqxmd.com/read/29150094/-geriatric-assessment-and-prognostic-scores-in-older-cancer-patient-additional-support-to-the-therapeutic-decision
#5
REVIEW
Frédéric Pamoukdjian, Evelyne Liuu, Philippe Caillet, Mathilde Gisselbrecht, Stéphane Herbaud, Pascaline Boudou-Rouquette, Laurent Zelek, Elena Paillaud
Cancer is a disease of the elderly as demonstrated by the epidemiological evolution of Western countries. Indeed, two third of cancers newly diagnosed occur over 65 years. However, older cancer patients have been often excluded from clinical trials in oncology and the extrapolation of cancer treatments in this population remains difficult in practice. Scientific societies recommend that a comprehensive geriatric assessment (CGA) be performed in patients aged 70 and over and selected using screening tools for frailty such as the G8 index...
November 14, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/29149132/lifelong-impression-remembering-one-of-our-own-during-the-holiday-season%C3%A2
#6
Mai-Fung Ho-Law
In life, meeting someone who truly possesses the gift of teaching is a blessing. As an exceptional mentor and role model, this person will inspire us to be the best that we can be and make us want to be better human beings. As oncology nurses, we have the honor of caring for patients who have been devastated by the diagnosis of cancer. Establishing deep connections with some of these patients will enrich and give more meaning to our own lives. 
.
December 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/29149131/genetics-and-genomics-an-oncology-nurse-s-journey-in-practice
#7
Suzanne M Mahon
BACKGROUND: Cancer genetics and genomics are now an integral component of oncology care. Genetics and genomics guide recommendations not only for cancer prevention and early detection, but also for cancer treatment. 
. OBJECTIVES: This article documents the personal experiences of an oncology nurse who has worked in cancer prevention and early detection since the 1990s and describes the many changes that have occurred in cancer-related genetic and genomic care during that time...
December 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/29149123/precision-medicine-accelerating-the-science-to-revolutionize-cancer-care%C3%A2
#8
Jeannine M Brant, Deborah K Mayer
BACKGROUND: Precision medicine in cancer care uses specific information about a person's tumor to help diagnose, plan treatment, prognosticate, and surveil throughout the cancer trajectory. Applications exist for cancer prevention, early detection, cancer treatment, and supportive care. Several national initiatives (e.g., National Cancer Moonshot Initiative) support these efforts to accelerate this science forward.
. OBJECTIVES: This article presents an overview of the way in which precision medicine is revolutionizing cancer care...
December 1, 2017: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/29140483/integrative-whole-person-oncology-care-in-the-uk
#9
Catherine Zollman, Axel Walther, Helen E Seers, Rachel C Jolliffe, Marie J Polley
The term "whole-person cancer care"-an approach that addresses the needs of the person as well as treating the disease-is more widely understood in the United Kingdom than its synonym "integrative oncology." The National Health Service (NHS) provides free access to care for all, which makes it harder to prioritize NHS funding of whole-person medicine, where interventions may be multimodal and lacking in cost-effectiveness data. Despite this, around 30% of cancer patients are known to use some form of complementary or alternative medicine (CAM)...
November 1, 2017: Journal of the National Cancer Institute. Monographs
https://www.readbyqxmd.com/read/29135296/-ischaemic-heart-disease-in-cancer-patients-questions-and-problems
#10
Petra Gulácsi-Bárdos, Miklós Szokol, Mária Lódi, Dániel Czuriga, István Czuriga, István Édes, András Nagy, Balázs Sármán
Cardiovascular and oncologic diseases are the causes of more than 50 percent of mortality in Europe. In 2015 oncologic and cardiovascular mortality reached 70 percent in Hungary. Patients who receive anticancer therapies are at a 2- to 7-fold greater long-term risk of acute coronary syndrome; also concomittant oncologic diseases further increase the mortality of myocardial infarction. Unfortunately there is not enough data concerning cardiovascular treatment of oncologic patients because they were excluded from most of the studies and registries...
October 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/29134826/cancer-patients-recommendations-for-nature-based-design-and-engagement-in-oncology-contexts-qualitative-research
#11
Sarah Blaschke, Clare C O'Callaghan, Penelope Schofield
OBJECTIVES: To explore cancer patients' recommendations for nature engagement based on their subjective nature experiences and observations in the cancer setting. The rationale was to gain practical insight for delineating relevant and translatable nature-based care and design opportunities in oncology contexts. BACKGROUND: Innovative cancer care services are needed to respond to growing demand and shifting healthcare needs. Engagement with nature has shown multiple health benefits and presents a promising opportunity for application in healthcare to improve outcomes...
January 1, 2017: HERD
https://www.readbyqxmd.com/read/29112544/european-guidelines-on-perioperative-venous-thromboembolism-prophylaxis-day-surgery-and-fast-track-surgery
#12
Linas Venclauskas, Juan V Llau, Jean-Yves Jenny, Per Kjaersgaard-Andersen, Øivind Jans
: In recent years, day surgery and fast-track surgery have experienced a continuous increase in volume. Many procedures are now performed on an outpatient protocol, including general, orthopaedic, oncological, reconstructive or vascular surgery. The management of these patients is safe, but the incidence of venous thromboembolism in this population remains unknown. Several risk factors can be identified and stratified derived from studies of inpatient surgical management (e.g. Caprini score). Recommendations for thromboprophylaxis should be tailored from the assessment of both personal and procedure-related risk factors, although with a lack of evidence for application in outpatient management...
November 6, 2017: European Journal of Anaesthesiology
https://www.readbyqxmd.com/read/29112494/proposal-for-the-creation-of-a-national-strategy-for-precision-medicine-in-cancer-a-position-statement-of-seom-seap-and-sefh
#13
Pilar Garrido, Azucena Aldaz, Miguel Ángel Calleja, Enrique De Álava, María Jesús Lamas, Miguel Martín, Xavier Matías-Guiu, José Palacios, Ruth Vera
Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person. Precision medicine is transforming clinical and biomedical research, as well as health care itself from a conceptual, as well as a methodological viewpoint, providing extraordinary opportunities to improve public health and lower the costs of the healthcare system. However, the implementation of precision medicine poses ethical-legal, regulatory, organizational and knowledge-related challenges...
November 1, 2017: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/29110627/the-impact-of-translational-research-in-breast-cancer-care-can-we-improve-the-therapeutic-scenario
#14
Francesco Perri, Giuseppe Buono, Francesco Schettini, Grazia Arpino, Roberto Bianco, Carmen Criscitiello, Sabino De Placido, Mario Giuliano
Traditionally, breast cancer (BC) is divided into different immunohistochemically (IHC)-defined subtypes, according to the expression of hormone receptors and overexpression/amplification of human epidermal growth factor receptor 2 (HER2), with crucial therapeutic implications. In the last few years, the definition of different BC molecular subgroups within the IHC-defined subtypes and the identification of the important role that molecular heterogeneity can play in tumor progression and treatment resistance have inspired the search for personalized therapeutic approaches...
November 2, 2017: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/29110277/meta-analysis-of-local-invasive-breast-cancer-recurrence-after-electron-intraoperative-radiotherapy
#15
Jay K Harness, Kalatu Davies, Christina Via, Elizabeth Brooks, April Zambelli-Weiner, Chirag Shah, Frank Vicini
BACKGROUND: Electron intraoperative radiotherapy (IORT) can be used during breast conserving surgery to treat early-stage invasive breast cancer. Using data from current clinical and observational studies, this study aimed to assess the impact of single-fraction electron IORT on local recurrence rates. METHODS: Studies on single-fraction electron IORT during breast conserving surgery were identified through a search of PubMed and Google Scholar, as well as through secondary referencing...
November 6, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29100553/translatability-score-revisited-differentiation-for-distinct-disease-areas
#16
REVIEW
Alexandra Wendler, Martin Wehling
BACKGROUND: Translational science supports successful transition of early biomedical research into human applications. In 2009 a translatability score to assess risk and identify strengths and weaknesses of a given project has been designed and successfully tested in case studies. The score elements, in particular the contributing weight factors, are heterogeneous for different disease areas; therefore, the score was individualized for six areas (cardiovascular, oncology, psychiatric, anti-viral, anti-bacterial/fungal and monogenetic diseases)...
November 3, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/29100299/coupling-to-a-cancer-selective-heparan-sulfate-targeted-branched-peptide-can-by-pass-breast-cancer-cell-resistance-to-methotrexate
#17
Lorenzo Depau, Jlenia Brunetti, Chiara Falciani, Silvia Scali, Giulia Riolo, Elisabetta Mandarini, Alessandro Pini, Luisa Bracci
Cancer-selective tetra-branched peptides, named NT4, can be coupled to different functional units for cancer cell imaging or therapy. NT4 peptides specifically bind to lipoprotein receptor-related proteins (LRP) receptors and to heparan sulfate chains on membrane proteoglycans and can be efficiently internalized by cancer cells expressing these membrane targets. Since binding and internalization of NT4 peptides is mediated by specific NT4 receptors on cancer cell membranes and this may allow drug resistance produced by drug membrane transporters to be by-passed, we tested the ability of drug-armed NT4 to by-pass drug resistance in cancer cell lines...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29097048/comparison-of-self-reported-data-on-student-doctor-network-to-objective-data%C3%A2-of-the-national-resident-matching-program
#18
Karna Sura, Lynn D Wilson, Inga S Grills
PURPOSE: To compare matching outcomes between self-reporting on Student Doctor Network (SDN) and objective data from the National Resident Matching Program (NRMP). MATERIALS AND METHODS: Data were collected from SDN starting in the 2010 to 2011 academic year and extending to the 2015 to 2016 academic year. A total of 193 radiation oncology applicants had reported data during the period. A total of four applicants (2.1%) did not match and were excluded from the analysis...
October 30, 2017: Journal of the American College of Radiology: JACR
https://www.readbyqxmd.com/read/29094172/essential-role-of-radiation-therapy-for-the-treatment-of-pancreatic-cancer-novel-study-concepts-and-established-treatment-recommendations
#19
REVIEW
Sophie Dobiasch, Nicole L Goerig, Rainer Fietkau, Stephanie E Combs
BACKGROUND: Pancreatic cancer is one of the most aggressive human tumors and the incidence has increased over the last 6 years. In the majority of cases the disease is already in an advanced stage at the time of diagnosis where surgery, the only curative treatment, is no longer an option and explains the still abysmal overall survival. The role of radiation therapy as treatment option for patients with pancreatic cancer is controversially discussed although radiation oncology has emerged as a central pillar in the combined oncological treatment...
November 1, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29092956/-personalized-cancer-therapy-a-publicly-available-precision-oncology-resource
#20
Katherine C Kurnit, Ann M Bailey, Jia Zeng, Amber M Johnson, Md Abu Shufean, Lauren Brusco, Beate C Litzenburger, Nora S Sánchez, Yekaterina B Khotskaya, Vijaykumar Holla, Amy Simpson, Gordon B Mills, John Mendelsohn, Elmer Bernstam, Kenna Shaw, Funda Meric-Bernstam
High-throughput genomic and molecular profiling of tumors is emerging as an important clinical approach. Molecular profiling is increasingly being used to guide cancer patient care, especially in advanced and incurable cancers. However, navigating the scientific literature to make evidence-based clinical decisions based on molecular profiling results is overwhelming for many oncology clinicians and researchers. The Personalized Cancer Therapy website (www.personalizedcancertherapy.org) was created to provide an online resource for clinicians and researchers to facilitate navigation of available data...
November 1, 2017: Cancer Research
keyword
keyword
1504
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"